A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066

• Drug: PF-02341066
  
  Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
  Other Name: Not Specified
• Drug: PF-02341066
  
  Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
  Other Name: Not Specified
• Drug: PF-02341066
  
  Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
  Other Name: Not Specified

Inclusion Criteria:

• Healthy male subjects, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg

Exclusion Criteria:

• Subjects who are smoking,
• Subjects with evidence of disease,
• Subjects with conditions affecting absorption,
• Subjects with treatment with other investigational drug within 30 days,
• Subjects with history of regular alcohol consumption,
• Subjects with use of prescription, nonprescription drugs and dietary supplement within 28 days,
• Subjects with blood donation of approximately 400 mL within 3 months or 200 mL within 1 month prior to dosing